Ultragenyx Pharmaceutical (RARE) Interest Coverage Ratio (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Interest Coverage Ratio of 8.05 for Q1 2026, up 21.21% year-over-year from 6.64 in Q1 2025, and down 38.31% quarter-over-quarter from 5.82 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Interest Coverage Ratio for 14 consecutive years, with 8.05 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 21.21% year-over-year to 8.05; the TTM figure through Mar 2026 stood at 8.17 (up 2.71% YoY), while the FY2025 annual figure was 8.63, down 1.42% from the prior year.
- Interest Coverage Ratio declined to 8.05 in Q1 2026 per RARE's latest filing, from 5.82 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 5.82 in Q4 2025 and bottomed at 20.75 in Q1 2022.
- Historically, Interest Coverage Ratio has averaged 10.33 across 5 years, with a median of 9.17 in 2022.
- On a YoY basis, Interest Coverage Ratio climbed as much as 65.97% in 2022 and fell as far as 81.25% in 2022.
- Ultragenyx Pharmaceutical's Interest Coverage Ratio stood at 9.17 in 2022, then grew by 23.34% to 7.03 in 2023, then dropped by 12.33% to 7.9 in 2024, then gained by 26.35% to 5.82 in 2025, then sank by 38.31% to 8.05 in 2026.
- Business Quant data shows RARE's Interest Coverage Ratio at 8.05 in Q1 2026, 5.82 in Q4 2025, and 12.08 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -3.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.41 |
| Mar 31, 2026 | -8.05 |
| Dec 31, 2025 | -5.82 |
| Sep 30, 2025 | -12.08 |
| Jun 30, 2025 | -7.68 |
| Mar 31, 2025 | -10.21 |
| Dec 31, 2024 | -7.90 |
| Sep 30, 2024 | -8.40 |
| Jun 30, 2024 | -7.29 |
| Mar 31, 2024 | -10.43 |
| Dec 31, 2023 | -7.03 |
| Sep 30, 2023 | -8.21 |
| Jun 30, 2023 | -9.62 |
| Mar 31, 2023 | -9.86 |
| Dec 31, 2022 | -9.17 |
| Sep 30, 2022 | -15.52 |
| Jun 30, 2022 | -17.62 |
| Mar 31, 2022 | -20.75 |
| Dec 31, 2021 | -26.96 |
| Sep 30, 2021 | -10.35 |